|
Patent landscape, scope, and claims: |
United States Patent 9,199,977: Scope, Claims, and Patent Landscape for Luliconazole Crystal Technology
What does US 9,199,977 claim in plain scope terms?
US 9,199,977 is a solid-state, crystal-form patent on luliconazole. The claim set is built around (i) a specific crystal habit and (ii) a quantitative powder X-ray diffraction (PXRD) intensity relationship for a defined set of lattice planes, plus (iii) a monoclinic crystal system restriction, and (iv) direct product and downstream method coverage.
At a high level, the enforceable subject matter is: luliconazole crystals defined by recrystallization conditions (alcohol ± water) and structural fingerprinting (PXRD integrated intensity ratios and a preferred growth plane), with coverage extending to API and formulation production steps that use that crystal form.
Claim map (from the text provided)
| Claim |
Claimed invention type |
Core technical definition used to delimit scope |
| 1 |
Crystal (solid form) |
Luliconazole crystal with a specified “crystal growth plane” (021), recrystallized from alcohol optionally containing water |
| 2 |
Crystal (crystal quality / fingerprint) |
PXRD-based quantitative constraint: I(021) / sum of selected peak intensities ≥ 1/3 over planes listed; 2θ window 5 to 35° with CuKα |
| 3 |
Crystal (system) |
Monoclinic crystal system |
| 4 |
API composition |
API containing the claimed crystal of claim 1 |
| 5 |
Use in process |
Method for producing a pharmaceutical composition by dissolving the claimed crystal in a solvent |
This structure is typical of crystal-form families: the claims focus on defining the solid form by crystallization method and measurable diffraction behavior, then broaden outward to API and basic formulation processing.
Claim 1: What crystal-form boundary does the growth-plane requirement set?
Claim 1 anchors the invention on a luliconazole crystal “represented by the following formula” (not reproduced in your excerpt, but the structure is luliconazole). The novelty and enforceability sit in two constraints:
-
Preparation / recrystallization constraint
- “recrystallized from alcohol which optionally contains water”
- This does not limit to a named alcohol, solvent concentration, temperature, or time in your excerpt, but it does narrow to alcohol-based recrystallization environments and explicitly permits water as an optional component.
-
Crystal habit constraint
- “such a crystal habit that (021) plane is a specific crystal growth plane”
- This is a directional morphology limitation. It ties the crystal habit to a specific growth plane index (021), which in crystallography typically refers to the Bravais lattice plane labeled by Miller indices.
Practical scope effect
- Manufacturing relevance: A competitor who makes a different polymorph or different crystal habit may avoid infringement if the (021) plane is not the specified “crystal growth plane.”
- Analytical relevance: Enforcing this claim usually requires demonstrating that the accused crystal exhibits the (021) plane as the growth plane associated with the observed habit. That can be tied to microscopy habit assessment and/or crystallographic growth inference, but the strongest objective delimiter in the claim set is actually claim 2’s PXRD intensity rule.
Claim 2: How does the PXRD intensity ratio define infringement risk?
Claim 2 is the most technically concrete limiter. It defines a threshold on the integrated intensities of multiple PXRD peaks corresponding to a specific set of planes.
Key elements of the claim language (as provided)
- PXRD method and conditions
- Powder X-ray diffractometry (PXRD)
- CuKα radiation
- Detection range: 2θ = 5 to 35°
- Peak set used
- Peaks corresponding to planes:
(001), (100), (10-1), (011), (110), (11-1), (10-2), (11-2), (020), (021), (20-2), (121), (013), (11-3), (221)
- Integrated intensities labeling
- I(001), I(100), I(10-1), I(011), I(110), I(11-1), I(10-2), I(11-2), I(020), I(021), I(20-2), I(121), I(013), I(11-3), I(221)
- Quantitative constraint
- “I(021) with respect to a sum total of” the same listed intensities is not less than 1/3
- i.e., effectively:
I(021) / (I(001)+I(100)+…+I(221)) ≥ 0.333
Practical scope effect
- This claim is a “fingerprint by ratio.” Even if a competitor produces crystals of the same general diffraction pattern, a shift in relative peak intensities due to preferred orientation, crystallite size distribution, amorphous content, residual solvent, or sample preparation can move the ratio below or above the 1/3 threshold.
- The claim has both breadth and fragility:
- Breadth: it does not require exact 2θ positions in your excerpt, only integrated intensity behavior across a defined plane set in a stated 2θ window.
- Fragility: ratio thresholds can be sensitive to experimental factors, but from an infringement perspective, that sensitivity is favorable to defendants only if reproducible testing can place the accused product below the threshold.
Risk analysis anchor
Claim 2 creates the largest “scientific battleground” in the portfolio:
- If an accused crystal form yields I(021) ratio ≥ 1/3 using the specified PXRD conditions and the same peak assignments, it is closer to infringement.
- If it yields < 1/3, it is closer to non-infringement, assuming the court construes the claim strictly and the plane assignments are consistent.
Claim 3: What does “monoclinic crystal system” add?
Claim 3 limits the crystal to the monoclinic system. This is a classic polymorph delimiter.
Practical scope effect
- If a competitor produces an orthorhombic, trigonal, tetragonal, triclinic, or hexagonal form, it would likely fall outside claim 3 (and likely outside claim 1’s growth-habit requirement if the habit corresponds to a different lattice).
- If a competitor produces a monoclinic form that still satisfies claim 2’s PXRD ratio, claim 1 and 2 could still be read on them depending on the (021) growth plane and recrystallization conditions.
Claim 4: How broad is the API product coverage?
Claim 4 covers: “An active pharmaceutical ingredient, containing the crystal as defined in claim 1.”
Scope mechanics
- This is product-by-content.
- It does not require a particular process step or formulation; it requires the API contain the defined crystal form (as per claim 1).
Strategic implications
- If a competitor sells luliconazole API made by a different process but the solid contains the defined crystal habit, claim 4 can still reach them.
- Conversely, a competitor could potentially use a different crystal habit or system (or a different diffraction behavior) to avoid claim 4 even if the final API is otherwise compositionally identical.
Claim 5: What is the enforceable process step?
Claim 5: “A method for producing a pharmaceutical composition, comprising a step of dissolving, in a solvent, the crystal as defined in claim 1.”
Scope mechanics
- It is narrow in that it is only directed to a dissolving step of the claimed crystal to produce a pharmaceutical composition.
- It does not claim additional formulation steps (mixing with excipients, milling, filtration, pH adjustment, crystallization during formulation, etc.) in your excerpt.
Practical scope effect
- Any manufacturing pathway that uses the claimed crystal and includes a dissolution step in a solvent to make a pharmaceutical composition risks coverage.
- If a competitor bypasses the dissolution of this specific crystal form (for example, uses a different solid form or a different process that does not involve dissolving the claimed crystal), it may avoid claim 5.
Overall scope characterization (what the patent covers tightly vs loosely)
Tight delimiters (strong novelty anchors)
- Crystal habit: (021) plane is the specific growth plane (claim 1)
- PXRD intensity ratio: I(021) / sum of specified intensities ≥ 1/3 over planes listed in 2θ 5-35° with CuKα (claim 2)
- Monoclinic system: (claim 3)
Looser outward coverage (use extensions)
- API containing the crystal (claim 4)
- Dissolving step using that crystal to make a pharmaceutical composition (claim 5)
In litigation terms, the extensions increase commercial reach, but the core validity and infringement hinge on claims 1 to 3’s solid-state definitions.
How does this fit into a typical luliconazole crystal patent landscape?
Even without additional family data in your excerpt, the architecture indicates the patent is part of a crystal-form strategy common for poorly water-soluble actives like azole antifungals. These families often have:
- one or more polymorph/crystal habit claims with PXRD thresholds,
- one or more API claims (product-by-content),
- and formulation processing claims (dissolution steps).
The scope you provided indicates the primary novelty is not luliconazole itself, but the solid-state form that results from a controlled recrystallization environment and is uniquely defined by PXRD ratios and morphology features.
Key competitive design-around vectors (based strictly on claim language)
These are the practical levers that map directly to the claim delimiters:
-
Change recrystallization solvent system
- Claim 1 requires recrystallization “from alcohol which optionally contains water.”
- A competitor using non-alcohol recrystallization (or solvent systems that are not alcohol-based) can argue lack of compliance with claim 1’s preparation constraint, and likely with the resulting habit.
-
Change crystal habit such that (021) is not the specific growth plane
- Claim 1 is habit-based. If the preferred growth plane differs, infringement risk drops.
-
Shift PXRD integrated intensity ratio below 1/3
- Claim 2 is a numeric threshold. Adjustments that change crystallite size, preferred orientation, residual solvent/water, or partial amorphization can change integrated peak intensities and their ratios.
-
Use a non-monoclinic crystal system
- Claim 3 adds a polymorph system limitation.
-
Avoid dissolving that specific claimed crystal form
- Claim 5 can be avoided if dissolution is not performed on the claimed crystal.
What is the strongest infringement argument?
Based on the excerpt, the strongest path would be:
- Demonstrate that the accused luliconazole material is a monoclinic crystal.
- Demonstrate the accused crystals show a habit where (021) plane is a specific crystal growth plane.
- Apply PXRD under CuKα, 2θ 5 to 35°, compute integrated intensities for the listed planes, and show:
- I(021) / ΣI(planes listed) ≥ 1/3.
If these three elements are met, claims 1-3 align, then claims 4 and 5 attach based on containment in API or dissolution into a pharmaceutical composition.
What is the strongest non-infringement argument?
A defense would likely focus on breaking at least one of the objective delimiters:
- show the PXRD integrated intensity ratio for the specified plane set is < 1/3 under the stated conditions,
- show the crystal system is not monoclinic,
- or show the growth habit does not make (021) the specific growth plane.
Because claim 2 is numeric, it is often the most litigable point.
Key Takeaways
- US 9,199,977 is a luliconazole crystal-form patent anchored on recrystallization from alcohol ± water and a crystal habit where (021) is the specific growth plane.
- Claim 2 provides the most enforceable delimiter: a PXRD integrated intensity ratio constraint where I(021) is at least 1/3 of the summed integrated intensities for a defined set of planes, measured with CuKα over 2θ = 5 to 35°.
- Claim 3 limits to monoclinic crystals, strengthening polymorph specificity.
- Claim 4 extends coverage to API containing the claimed crystal, and claim 5 extends to a dissolution step using that crystal to produce a pharmaceutical composition.
- The most direct design-arounds map to: changing solvent system away from alcohol ± water, altering habit so (021) is not the growth plane, shifting the PXRD intensity ratio below the threshold, or using a different crystal system.
FAQs
1) Does claim 5 require a full formulation recipe?
No. In your excerpt, claim 5 covers a method with a step of dissolving the claimed crystal in a solvent to produce a pharmaceutical composition.
2) Can a monoclinic luliconazole crystal avoid the patent?
Yes, if it does not meet the claim 1 habit requirement (021 as the specific growth plane) and/or the claim 2 PXRD intensity ratio threshold.
3) Is claim 2 dependent on exact peak positions?
Your excerpt defines 2θ range (5 to 35°) and peak assignments by planes, then constrains integrated intensities. It does not state a numeric requirement on exact 2θ positions in the provided text.
4) Does claim 4 protect finished products?
Not as written in your excerpt. Claim 4 is for API containing the crystal as defined in claim 1. Finished dosage claims are not shown here.
5) What analytical measurement most directly determines infringement for claims 1 to 3?
The PXRD integrated intensities for the specified plane set under CuKα and 2θ = 5 to 35° are central to claim 2, while monoclinic system determination and habit/growth plane evidence support claims 1 and 3.
References
[1] United States Patent 9,199,977, claims excerpt as provided in the prompt (claims 1-5 regarding luliconazole crystals, recrystallization from alcohol ± water, PXRD intensity ratio, monoclinic system, API containment, and dissolution-based method).
More… ↓
⤷ Start Trial
|
